DSDemi Sandel

Demi Sandel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Demi Sandel has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A mechanistic basis for CD8+ T cell expansion sensitivity as a predictor of HIV post-treatment control

    by Tin Phan, Nicole Pagane, Jasmine Kreig, Aurelien Marc, Macauley Locke, Michael J. Peluso, Demi A. Sandel, Amelia N. Deitchman, Rachel L. Rutishauser, Steven G. Deeks, et al.

    A key goal in HIV-1 cure research is to understand why some individuals control viral rebound after stopping antiretroviral therapy (ART). Recent human studies have identified responding CD8+ T cells expressing Ki-67 and the transcription factor TCF-1 as correlates of post-treatment control, but the mechanistic basis of this association remains unclear. Using the theoretical framework of Conway and Perelson, we fit mechanistic within-host models to viral load and CD8+ T cell data from 9 individuals in a combination immunotherapy trial following ART interruption. Although Ki-67 and TCF-1 measurements were not used for fitting, the inferred effector cell expansion sensitivity, i.e., the responsiveness of effector expansion to low antigen levels, shows a strong linear relationship with Ki-67 and TCF-1 levels at rebound (Pearson’s r ≈ 0.8). Building on this, we show analytically that the post-rebound viral load set point is inversely proportional to the effector cell expansion sensitivity, and thus strongly correlates with cycling (Ki-67+) CD8+ T cells (r ≈ –0.8) at rebound, and a subset that expresses TCF-1 (r ≈ –0.9). In effect, individuals with a larger proportion of CD8+ T cells responding to viral rebound, and a greater representation of TCF-1 expressing cells within the responding subset, achieve markedly lower viral set points through a higher effector cell expansion sensitivity. This mechanism is consistent with prior modeling in a non-intervention ATI setting, suggesting it may generalize across more rebound contexts. Our results provide a mechanistic explanation why both Ki-67+ responding CD8+ T cells and their TCF-1-expressing subset predict post-treatment control, linking clinical correlation to its underlying cause and highlighting Ki-67 and TCF-1 as potential early biomarkers of HIV immunotherapy success.

  • Open Access

    Immune activation during broadly neutralizing antibody-mediated HIV suppression prior to post-intervention control

    by Julia A. Wagner, Demi A. Sandel, Ravi K. Patel, George W. Gruenhagen, Rafael Tibúrcio, Shayleen S. Singh, Kaiti Schwartz, Michela Traglia, Pamela Milani, Clara Di Germanio, et al.

    Broadly neutralizing antibodies (bNAbs) have been associated with enhancement of HIV-specific T or B cell responses and sustained partial control of HIV replication in some people with HIV (PWH). The mechanisms through which bNAbs may potentiate host immunity in this context are not known. We previously reported the outcomes of a clinical trial in which ten PWH on antiretroviral therapy (ART) received a combination of immunotherapies including two bNAbs administered immediately preceding an analytic treatment interruption (ATI). After bNAb levels waned, seven participants exhibited varying degrees of post-intervention control of HIV linked to a robust expansion of activated CD8+ T cells in response to rebounding virus. To investigate the role of the bNAbs in enhancing endogenous immune responses, we looked for evidence of HIV-specific or broader immune activation during the period after ART was paused and prior to rebound when bNAbs were controlling HIV replication. At a timepoint early post-ART interruption and at least one month before virus emerged in plasma, we detected an increase in levels of plasma inflammatory proteins as well as phenotypic and transcriptional activation of innate and adaptive immune cells. Compared to non-controllers, post-intervention controllers demonstrated unique transcriptional activation patterns as well as differential longitudinal plasma inflammatory protein trends. No enhancement of HIV-specific T cell or antibody responses was observed in this window. This study identifies activated cell types and inflammatory pathways that are recruited early during bNAb-mediated HIV suppression and that may play a role in potentiating long-lasting HIV immune control after bNAb therapy. One Sentence Summary: In a combination immunotherapy trial with high rates of post-intervention control, bNAb-mediated HIV suppression was associated with increased immune activation compared to HIV suppression by ART.


  • Open Access

    Advances in Immune-Based Approaches for the Cure of HIV Infection

    by Julia A. Wagner, Demi A. Sandel, Amelia N. Deitchman, Rachel L. Rutishauser, Steven G. Deeks, Michael J. Peluso

    Despite significant advances in antiretroviral therapy, the need for a cure for HIV persists because of factors such as long-term antiretroviral therapy-related comorbidities, disease stigma, and inequities in access to care. Most cure efforts focus on inducing durable HIV remission (antiretroviral therapy-free viral control) either by augmenting immune function or reducing the HIV reservoir. In this review, we highlight immune-based cure interventions currently under investigation with a particular focus on those that have demonstrated the ability to induce durable HIV remission after analytic treatment interruption, here termed “post-intervention control”. While current cure interventions are generally complex, expensive, and not easily scalable, they provide critical “proof of principle” that a cure for HIV is possible. Continuing to make studies of HIV cure a funding priority is important, we believe, as continued optimization of cure interventions should eventually lead to a cure that is simple, safe, effective, affordable, and scalable. In addition, we highlight critical features in clinical trial design and pharmacokinetics/pharmacodynamics that should be considered prior to clinical trial implementation.


  • Top Cited Papers
    Open Access

    Correlates of HIV-1 control after combination immunotherapy

    by M. J. Peluso, D. A. Sandel, A. N. Deitchman, S. J. Kim, T. Dalhuisen, H. P. Tummala, R. Tibúrcio, L. Zemelko, G. M. Borgo, S. S. Singh, et al.

    The identification of therapeutic strategies to induce sustained antiretroviral therapy (ART)-free control of HIV infection is a major priority 1 . Combination immunotherapy including HIV vaccination, immune stimulation, latency reversal and passive transfer of broadly neutralizing antibodies (bNAbs) has shown promise in non-human primate models 2–6 , but few studies have translated such approaches into people. Here we performed a single-arm, proof-of-concept study in ten people living with HIV on ART, combining the following three approaches: (1) therapeutic vaccination with an HIV Gag conserved element-targeted DNA + IL-12 prime/modified vaccinia Ankara (MVA) boost regimen followed by (2) administration of two bNAbs (10-1074, VRC07-523LS) and a toll-like receptor 9 agonist (lefitolimod) during ART suppression, followed by (3) repeat bNAb administration at the time of ART interruption (Clinicaltrials.gov: NCT04357821 ). Seven out of the ten participants exhibited post-intervention control after pausing ART, independent of residual bNAb plasma levels. Robust expansion of activated CD8 + T cells early in response to rebounding virus correlated with a lower median viral load after peak viraemia off ART. These data suggest that combination immunotherapy approaches might prove effective in inducing sustained control of HIV by slowing rebound and improving CD8 + T cell responses, and that these approaches should continue to be optimized.


  • Open Access

    Combination immunotherapy induces post-intervention control of HIV

    by Michael Peluso, Demi Sandel, Amelia Deitchman, Sun Jin Kim, Thomas Dalhuisen, Hari Tummala, Rafael Tiburcio, Lily Zemelko, Gina Borgo, Shayleen Singh, et al.

    The identification of therapeutic strategies to induce sustained antiretroviral therapy (ART)-free control of HIV infection is a major priority. Combination immunotherapy including HIV vaccination, immune stimulation/latency reversal, and passive transfer of broadly neutralizing antibodies (bNAbs) has shown promise in non-human primate models, but few studies have translated such approaches into people. Here, we performed a single-arm, proof-of-concept combination study of these three approaches in ten people with HIV on ART that included (1) therapeutic vaccination with an HIV/Gag conserved element (CE)-targeted DNA+IL-12 prime/MVA boost regimen followed by (2) administration of two bNAbs (10-1074 and VRC07-523LS) and a toll-like receptor 9 (TLR9) agonist (lefitolimod) during ART suppression, followed by (3) repeat bNAb administration at the time of ART interruption. Seven of the ten participants exhibited partial (low viral load set point) or complete (aviremic) post-intervention control after stopping ART, independent of residual bNAb plasma levels. Robust expansion of activated CD8+ T cells early in response to rebounding virus correlated with lower viral load set points. These data suggest that combination immunotherapy approaches might prove effective to induce sustained control of HIV by slowing rebound and improving CD8+ T cell responses, and that these approaches should continue to be optimized.


  • Open Access

    Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation

    by Alex M. Jaeger, Lauren Stopfer, Sunmin Lee, Giorgio Gaglia, Demi Sandel, Sandro Santagata, Nancy U. Lin, Jane B. Trepel, Forest White, Tyler Jacks, et al.

  • Open Access

    Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation

    by Alex M. Jaeger, Lauren Stopfer, Sunmin Lee, Giorgio Gaglia, Demi Sandel, Sandro Santagata, Nancy U. Lin, Jane B. Trepel, Forest White, Tyler Jacks, et al.

  • Open Access

    Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation

    by Alex M. Jaeger, Lauren Stopfer, Sunmin Lee, Giorgio Gaglia, Demi Sandel, Sandro Santagata, Nancy U. Lin, Jane B. Trepel, Forest White, Tyler Jacks, et al.

    PBMC RNAseq Raw Transcript Counts

  • Open Access

    Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation

    by Alex M. Jaeger, Lauren Stopfer, Sunmin Lee, Giorgio Gaglia, Demi Sandel, Sandro Santagata, Nancy U. Lin, Jane B. Trepel, Forest White, Tyler Jacks, et al.

    MC38 Tumors Pan Cancer Immune Profiling Codeset

  • Open Access

    Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation

    by Alex M. Jaeger, Lauren Stopfer, Sunmin Lee, Giorgio Gaglia, Demi Sandel, Sandro Santagata, Nancy U. Lin, Jane B. Trepel, Forest White, Tyler Jacks, et al.

    PBMC RNAseq DESeq2 Data Tables